Affymetrix Technology Used To Discover Molecular Mechanisms Of Liver Disease
Jul 4th 2008Drug InformationLiver Disease / Hepatitis
Affymetrix Inc. (Nasdaq:AFFX) announced that a team of researchers at the Fraunhofer Institute in Germany is using Affymetrix’ Whole Transcript (WT) gene expression technology to better understand the molecular basis of drug-induced liver injury (DILI). The ultimate goal of the project is to develop a diagnostic array that can detect signals of liver toxicity earlier and more accurately than traditional techniques.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
